{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:16:55Z","timestamp":1794777415374,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["085860"],"award-info":[{"award-number":["085860"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"crossref","award":["SP4252"],"award-info":[{"award-number":["SP4252"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Myositis Support Group","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["14518"],"award-info":[{"award-number":["14518"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["20164"],"award-info":[{"award-number":["20164"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000852","name":"The Henry Smith Charity","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000852","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001279","name":"Great Ormond Street Hospital Charity","doi-asserted-by":"publisher","award":["V1268"],"award-info":[{"award-number":["V1268"]}],"id":[{"id":"10.13039\/501100001279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015391","name":"The Myositis Association","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cure JM","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3\u2009months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician\u2019s global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman\u2019s test for repeated measures analysis of variance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to baseline, there were improvements at 6 and 12\u2009months in skin disease (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u200915.52,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00043), global disease (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u20098.14,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017) and muscle disease (CMAS\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u200917.02,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002 and MMT\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u200910.56,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) in infliximab patients. For patients who switched from infliximab to adalimumab, there was improvement in global disease activity (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u20096.73,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and trends towards improvement in CMAS, MMT8 and modified DAS. The median initial prednisolone dose was 6 [0\u201310] mg, and final was 2.5 [0\u20137.5] mg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Fifty-four per cent of patients had a reduction in the number and\/or size of calcinosis lesions. Twenty-five per cent switched their anti-TNF treatment from infliximab to adalimumab. 66.7%of the switches were to improve disease control, 26.7% due to adverse events and 6.6% due to patient preference. A total of 13.9 adverse reactions occurred in 100 patient-years, of which 5.7 were considered serious.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reductions in muscle and skin disease, including calcinosis, were seen following treatment with infliximab and adalimumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02164-5","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T08:02:37Z","timestamp":1586937757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients"],"prefix":"10.1186","volume":"22","author":[{"name":"for the Juvenile Dermatomyositis Research Group (JDRG)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Campanilho-Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire T.","family":"Deakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Simou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa A.","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"9631","key":"2164_CR1","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201\u201312.","journal-title":"Lancet."},{"issue":"1","key":"2164_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/rheumatology\/keq261","volume":"50","author":"N Martin","year":"2011","unstructured":"Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years\u2019 experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford). 2011;50(1):137\u201345.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2164_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"FB Enders","year":"2017","unstructured":"Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2164_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12016-016-8530-2","volume":"52","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Modern therapies for idiopathic inflammatory myopathies (IIMs): role of biologics. Clin Rev Allergy Immunol. 2017;52(1):81\u20137.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9194","key":"2164_CR5","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932\u20139.","journal-title":"Lancet"},{"issue":"6 Suppl 28","key":"2164_CR6","first-page":"S106","volume":"20","author":"J Brandt","year":"2002","unstructured":"Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S106\u201310.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"2164_CR7","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","volume":"43","author":"LM Pachman","year":"2000","unstructured":"Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43(10):2368\u201377.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2164_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1006\/clim.2001.5063","volume":"100","author":"F TO","year":"2001","unstructured":"Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol. 2001;100(2):236\u20139.","journal-title":"Clin Immunol"},{"key":"2164_CR9","doi-asserted-by":"publisher","first-page":"369432","DOI":"10.1155\/2012\/369432","volume":"2012","author":"B De Paepe","year":"2012","unstructured":"De Paepe B, Creus KK, De Bleecker JL. The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol. 2012;2012:369432.","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"2164_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1067\/mjd.2002.122196","volume":"47","author":"RE Fisler","year":"2002","unstructured":"Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2164_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","volume":"47","author":"P Riley","year":"2008","unstructured":"Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2164_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"2164_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"2164_CR14","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.20179","volume":"50","author":"AM Huber","year":"2004","unstructured":"Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004;50(5):1595\u2013603.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2164_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20035","volume":"62","author":"LG Rider","year":"2010","unstructured":"Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 2010;62(4):465\u201372.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2164_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/art.23248","volume":"59","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Paediatric Rheumatology International Trials Organisation\/American College of Rheumatology\/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59(1):4\u201313.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2164_CR17","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50(7):2281\u201390.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2164_CR18","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1136\/ard.2011.153718","volume":"70","author":"CG Lam","year":"2011","unstructured":"Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2164_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","volume":"15","author":"CH Spencer","year":"2017","unstructured":"Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, et al. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017;15(1):50.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"5","key":"2164_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.40418","volume":"70","author":"CT Deakin","year":"2018","unstructured":"Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA, Juvenile Dermatomyositis Research Group. Efficacy and safety of cyclophosphamide in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70(5):785\u201393.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2164_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-017-0199-4","volume":"15","author":"AB Orandi","year":"2017","unstructured":"Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"2164_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","volume":"9","author":"L Lichtenstein","year":"2015","unstructured":"Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: systematic review. J Crohn\u2019s Colitis. 2015;9(9):806\u201315.","journal-title":"J Crohn\u2019s Colitis"},{"key":"2164_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.","journal-title":"Arthritis Res Ther"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02164-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:27:19Z","timestamp":1618432039000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02164-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2164"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02164-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed written parental consent and age-appropriate assent were obtained. This research was approved by the UK Northern & Yorkshire Medical Research and Ethics Committee. This manuscript does not contain data from any individual person.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}